- Report
- February 2025
- 315 Pages
Global
From €4213EUR$4,799USD£3,615GBP
- Report
- January 2025
- 456 Pages
Global
From €4345EUR$4,950USD£3,729GBP
- Report
- May 2025
- 188 Pages
Global
From €3112EUR$3,545USD£2,670GBP
€3458EUR$3,939USD£2,967GBP
- Report
- July 2025
- 285 Pages
Global
From €5135EUR$5,850USD£4,407GBP
- Report
- July 2025
- 370 Pages
Global
From €5135EUR$5,850USD£4,407GBP
- Report
- February 2025
- 200 Pages
Global
From €3941EUR$4,490USD£3,382GBP
- Report
- July 2025
- 373 Pages
Global
From €5135EUR$5,850USD£4,407GBP
- Report
- July 2025
- 380 Pages
Global
From €5135EUR$5,850USD£4,407GBP
- Report
- July 2025
- 282 Pages
Global
From €5135EUR$5,850USD£4,407GBP
- Report
- June 2025
- 400 Pages
Global
From €4344EUR$4,949USD£3,728GBP
- Report
- April 2025
- 125 Pages
United States
From €2853EUR$3,250USD£2,448GBP
- Report
- November 2021
- 261 Pages
Global
From €2304EUR$2,625USD£1,977GBP
€4609EUR$5,250USD£3,955GBP
- Report
- April 2024
- 183 Pages
Global
From €3358EUR$3,825USD£2,881GBP
€3950EUR$4,500USD£3,390GBP
- Report
- January 2024
- 200 Pages
Global
From €3643EUR$4,150USD£3,126GBP
- Book
- April 2020
- 272 Pages
- Book
- August 2021
- 312 Pages
- Book
- February 2024
- 640 Pages
- Book
- September 2023
- 288 Pages

Hepatocellular Carcinoma (HCC) is a type of cancer that originates in the liver. It is the most common form of liver cancer and is the third leading cause of cancer-related deaths worldwide. HCC is typically diagnosed in individuals with underlying liver diseases such as cirrhosis, hepatitis B or C, and non-alcoholic fatty liver disease. Treatment options for HCC include surgery, radiation therapy, chemotherapy, and targeted therapy.
The oncology market for HCC is highly competitive, with a number of companies offering treatments and therapies. These include AbbVie, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche, and Takeda. Additionally, there are a number of smaller companies that are developing novel therapies for HCC, such as Aduro Biotech, ArQule, and Oncoceutics. Show Less Read more